Navigation Links
LPGA Pro, Jill McGill, Encourages Indoor and Outdoor Allergy Sufferers to Challenge Their Course

ATLANTA and BRIDGEWATER, N.J., Feb. 28 /PRNewswire-FirstCall/ -- Ladies Professional Golf Association (LPGA) player Jill McGill and the Asthma and Allergy Foundation of America (AAFA) have teamed up with UCB and sanofi-aventis to launch the Challenge Your Course campaign. The campaign is designed to encourage indoor and outdoor allergy sufferers to visit their physician to examine the way they currently manage their symptoms.

Many people suffer from the symptoms associated with indoor and outdoor allergies, such as sneezing, runny nose, itchy eyes and nose. Experts estimate that allergies affect as many as 40 million people in the United States.

"As a golfer, I'm always surrounded by grass and when I'm traveling to different cities on tour I never know how my indoor and outdoor allergies will react. There have been many times that my symptoms have been so bad that I had a hard time even being on the golf course," says Jill McGill, LPGA golfer and a long time nasal allergy sufferer. "With such a severe runny nose, itchy eyes and sneezing, it was very difficult for me to concentrate and physically swing the club. It became such a problem that I finally decided to start treating my nasal allergies and went to see my physician. Now I'm teaming up with the Asthma and Allergy Foundation of America to help educate other people with indoor and outdoor allergies."

Through Challenge Your Course, indoor and outdoor allergy sufferers are encouraged to visit their physician to review their current allergy management routine. Nasal allergy sufferers can learn about available treatment options, including XYZAL(R) (levocetirizine dihydrochloride), a new once-daily prescription medication indicated for the relief of symptoms associated with indoor and outdoor allergies, as well as the treatment of uncomplicated manifestations of chronic idiopathic urticaria (CIU) in adults and children 6 years and older. This program includes a variety of helpful information and tools including an allergy treatment scorecard, tips for managing indoor and outdoor allergies, as well as additional background on Jill McGill. Anyone can log on to to determine if they are managing their indoor and outdoor allergies optimally.

"Jill is not alone as 60 percent of patients using a prescription medication to treat their seasonal allergies reported they are interested in finding a new prescription nasal allergy treatment," said Mike Tringale, director of external affairs for AAFA, the leading allergy patient organization. "With so many people dissatisfied with their current indoor and outdoor allergy treatment options, we are very excited to work with Jill to motivate patients to ensure they are effectively managing their nasal allergies."

Challenge Your Course will provide nasal allergy sufferers with useful tips including:

-- Keep windows closed to prevent pollens or molds from drifting into your


-- Use air conditioners as much as possible to clean, cool and dry the air

in your home

-- Try to avoid being outside on days when pollen count and humidity are

reported to be high, or on windy days when pollen and dust gets blown


-- Don't hang your clothes outside to dry, as they may collect pollen and


-- Minimize early morning activities when pollen is usually emitted

-- Avoid mowing your lawn or being around freshly cut grass; mowing stirs

up pollens and mold

-- If you have a pet, keep them out of your bedroom as much as possible to

avoid being exposed to animal dander throughout the night

Challenge Your Course is supported by UCB and sanofi-aventis, the makers of XYZAL(R) (levocetirizine dihydrochloride).

About XYZAL(R)

Indications and Important Safety Information

XYZAL(R) is indicated for the relief of symptoms associated with allergic rhinitis (seasonal and perennial) and the treatment of uncomplicated skin manifestations of chronic idiopathic urticaria in adults and children 6 years of age and older.

The use of XYZAL(R) is contraindicated in: patients with a known hypersensitivity to levocetirizine or any of the ingredients of XYZAL(R) or to cetirizine (observed reactions range from urticaria to anaphylaxis); patients with end-stage renal impairment at less than 10 mL/min creatinine clearance or patients undergoing hemodialysis; and pediatric patients aged 6 to 11 years with impaired renal function.

Patients should be cautioned against engaging in hazardous occupations requiring complete mental alertness and motor coordination, such as operating machinery or driving a motor vehicle, after ingestion of XYZAL(R). Concurrent use of XYZAL(R) with alcohol or other central nervous system (CNS) depressants should be avoided because additional reductions in alertness and additional impairment of CNS performance may occur.

In clinical trials, the most common adverse reactions in greater than or equal to 2% of adult and adolescent patients (12 years of age and older) taking XYZAL(R) 2.5 mg, XYZAL(R) 5 mg, or placebo were somnolence (5%, 6%, 2%), nasopharyngitis (6%, 4%, 3%), fatigue (1%, 4%, 2%), dry mouth (3%, 2%, 1%), and pharyngitis (2%, 1%, 1%), respectively.

In clinical trials, the most common adverse reactions in greater than or equal to 2% of pediatric patients (6-12 years of age) taking XYZAL(R) 5 mg included pyrexia (4% vs 2% placebo), cough (3% vs < 1% placebo), somnolence (3% vs < 1% placebo), and epistaxis (2% vs < 1% placebo).

Please visit for full prescribing information.

About Allergic Conditions

Many people suffer from the symptoms associated with common allergic conditions. The immune system of allergy sufferers over-reacts to something in the environment, leading to symptoms that affect their respiratory system, eyes, or skin. Experts estimate indoor and outdoor allergies affect as many as 40 million people in the United States.

Seasonal allergic rhinitis (SAR), commonly referred to as "hay fever" or "outdoor allergies," is the most common form of allergic rhinitis. By definition, SAR includes allergies to seasonal pollens like grass, trees, and weeds, as well as mold. Perennial Allergic Rhinitis (PAR) is sometimes referred to as "year round" or "indoor allergies" and is characterized by allergic symptoms that last longer than four weeks. House dust mites, animal dander, and mold most commonly trigger PAR. Chronic Idiopathic Urticaria (CIU) is most commonly known as "chronic hives of unknown origin" and is defined as the occurrence of daily, or almost daily, wheals and itching for at least six weeks with no obvious causes.

About UCB

UCB is a global leader in the biopharmaceutical industry dedicated to the research, development and commercialization of innovative pharmaceutical and biotechnology products in the fields of central nervous system disorders, allergy/respiratory diseases, immune and inflammatory disorders and oncology. Employing approximately 12,000 people in more than 40 countries, UCB achieved revenue of $4.6 billion (3.5 billion euro) in 2006 on a pro forma basis. UCB is listed on the Euronext Brussels Exchange. Worldwide headquarters is located in Brussels, Belgium; U.S. headquarters is located in Atlanta, Georgia. For more information about UCB, visit

About sanofi-aventis

Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

About AAFA

The Asthma and Allergy Foundation of America (AAFA),, is the leading nonprofit consumer and patient organization fighting asthma and allergic diseases. AAFA provides free consumer information, patient education, and funding for research to find cures.

For Further Information, Please Contact:

Lynn Duran


Mobile: 678-571-0116


Susan Brooks


Phone: 908-981-6566


SOURCE sanofi-aventis
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Circassia Initiates Phase II Clinical Study With Novel Anti-Allergy Technology
2. One Year On, ALLERCA Hypoallergenic Cats Bring Sneeze Free Companionship to Allergy and Asthma Sufferers
3. The Food Allergy & Anaphylaxis Network (FAAN) and Verus Pharmaceuticals Work Together to Raise Awareness of Food Allergies
4. Organogenesis Debuts Educational Campaign for Sufferers of Chronic Leg and Foot Ulcers
5. American and European Parkinsons Sufferers Find Chinese Stem Cell Treatment Effective, Proving Western Debates Moot
6. Unmet Needs Provide Challenges and Opportunities for Rheumatoid Arthritis Drug Developers According to MedPredict Report
7. Barr Confirms Patent Challenge of Avodart(R) Soft Gelatin Capsules, 0.5mg
8. MIT researcher addresses biomedical engineering challenges
9. GPhA Annual Meeting Focuses on Industry Opportunities and Challenges for 2008
10. Challenge Spreadable Butter Now Features Marteks lifesDHA(TM)
11. White Paper Details Infection Control Challenges Hospitals Must Address During Construction
Post Your Comments:
(Date:10/12/2017)... ... October 12, 2017 , ... ... United States multicenter, prospective clinical study that demonstrates the accuracy of the ... of identifying clinically significant acute bacterial and viral respiratory tract infections by ...
(Date:10/11/2017)... LINDA, CA (PRWEB) , ... October 11, 2017 ... ... to upregulate any gene in its endogenous context, enabling overexpression experiments and avoiding ... (CRISPRa) system with small RNA guides is transformative for performing systematic gain-of-function studies. ...
(Date:10/11/2017)... and LAGUNA HILLS, Calif. , Oct. 11, ... Research, London (ICR) and University of ... SkylineDx,s prognostic tool to risk-stratify patients with multiple myeloma (MM), ... nine . The University of Leeds ... funded by Myeloma UK, and ICR will perform the testing ...
(Date:10/10/2017)... CA (PRWEB) , ... October ... ... a development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, today ... of targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in collaboration ...
Breaking Biology Technology:
(Date:4/24/2017)... April 24, 2017 Janice Kephart ... with  Identity Strategy Partners, LLP (IdSP) , today ... without President Trump,s March 6, 2017 Executive ... , refugee vetting can be instilled with greater confidence, ... now, all refugee applications are suspended by until ...
(Date:4/18/2017)... April 18, 2017  Socionext Inc., a global expert in SoC-based ... edge server, the M820, which features the company,s hybrid codec technology. ... by Tera Probe, Inc., will be showcased during the upcoming Medtec ... show at the Las Vegas Convention Center ... Click here ...
(Date:4/13/2017)... MONICA, Calif. , April 13, 2017 ... New York will feature emerging and evolving ... Summits. Both Innovation Summits will run alongside the expo ... of speaker sessions, panels and demonstrations focused on trending ... coast,s largest advanced design and manufacturing event will take ...
Breaking Biology News(10 mins):